Eligibility and Testing

The Oncotype DX AR-V7 Nucleus Detect test detects whether your tumor will be resistant to androgen receptor (AR)-targeted therapies, such as XTANDI® or ZYTIGA®.*  It can be performed whenever your doctor is considering AR-targeted therapies for your treatment.

You may be a candidate for the AR-V7 Nucleus Detect test if:

  • You have metastatic castration-resistant prostate cancer (mCRPC).
  • Your doctor is considering whether AR-targeted therapies are right for you.
  • You’ve already undergone AR-targeted therapies, and your doctor is deciding whether to continue those treatments or recommend other treatment options.

Because tumors can adapt (and become resistant) to AR-targeted therapies over time, your doctor may recommend the AR-V7 Nucleus Detect test after each round of AR-targeted therapy treatment.

Talking to your doctor about the test

When discussing the AR-V7 Nucleus Detect test, you may want to ask your doctor the following questions:

  • If I am a candidate for the AR-V7 Nucleus Detect test, how could we use the test results to develop my treatment plan?
  • What are my treatment options? What do you suggest for me and why?
  • What are the benefits of each treatment option? What are the drawbacks/side effects of each one?
  • How long do side effects of each treatment option last? Do they go away once treatment is complete?

*Xtandi® is a registered trademark of Astellas Pharma, Inc. Zytiga® is a registered trademark of Johnson and Johnson.

Making cancer care smarter.®